Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement

Por Schwarz, Roderich E, Berlin, Jordan D, Lenz, Heinz J, Nordlinger, Bernard, Rubbia-Brandt, Laura, Choti, Michael A
Publicado em 2013

S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarc...

Por Leichman, Lawrence P., Goldman, Bryan H., Bohanes, Pierre O., Lenz, Heinz J., Thomas, Charles R., Billingsley, Kevin G., Corless, Christopher L., Iqbal, Syma, Gold, Philip J., Benedetti, Jacqueline K., Danenberg, Kathleen D., Blanke, Charles D.
Publicado em 2011

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fuoro-2′-deoxycytidine, administered with tetrahydrouridine

Por Newman, Edward M., Morgan, Robert J., Kummar, Shivaani, Beumer, Jan H., Blanchard, M. Suzette, Ruel, Christopher, El-Khoueiry, Anthony B., Carroll, Mary I., Hou, Jessie M., Li, Chun, Lenz, Heinz J., Eiseman, Julie L., Doroshow, James H.
Publicado no Cancer Chemother Pharmacol (2015)

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients

Por Rubinson, Douglas A., Hochster, Howard S., Ryan, David P., Wolpin, Brian M., McCleary, Nadine Jackson, Abrams, Thomas A., Chan, Jennifer A., Iqbal, Syma, Lenz, Heinz J., Lim, Dean, Rose, Jeffrey, Bekaii-Saab, Tanios, Chen, Helen X., Fuchs, Charles S., Ng, Kimmie
Publicado em 2013